BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 1-Year Low – Time to Sell?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) hit a new 52-week low on Thursday . The company traded as low as $6.30 and last traded at $6.76, with a volume of 1498632 shares. The stock had previously closed at $8.86.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Oppenheimer began coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. Raymond James Financial decreased their price target on shares of BridgeBio Oncology Therapeutics from $24.00 to $22.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, UBS Group downgraded shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a report on Wednesday, July 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.57.

BridgeBio Oncology Therapeutics Trading Down 23.7%

The business has a 50 day moving average price of $8.77 and a 200-day moving average price of $8.73. The company has a market cap of $541.95 million, a P/E ratio of -2.45 and a beta of 0.38.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. On average, sell-side analysts expect that BridgeBio Oncology Therapeutics, Inc will post -2.79 earnings per share for the current year.

Institutional Trading of BridgeBio Oncology Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of BBOT. Opaleye Management Inc. increased its holdings in shares of BridgeBio Oncology Therapeutics by 1,213.8% during the 2nd quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock worth $5,334,000 after acquiring an additional 646,718 shares during the last quarter. Armistice Capital LLC lifted its holdings in BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after purchasing an additional 588,000 shares during the last quarter. Laurion Capital Management LP boosted its position in BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after purchasing an additional 419,138 shares during the period. Catalio Capital Management LP acquired a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at $5,142,000. Finally, Paradigm Biocapital Advisors LP raised its position in shares of BridgeBio Oncology Therapeutics by 21.2% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after purchasing an additional 395,608 shares during the period. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.